Landmark Study Affirms MolecuLight's Efficacy in Real-Time Bacterial Detection for Improved Wound Management

MolecuLight Inc. Ontario

is a privately owned medical imaging company with a global presence that manufactures and commercializes the MolecuLight i:X® and DX™ wound imaging devices. These are the only Class II FDA-cleared point-of-care imaging devices for the real-time detection of elevated bacterial burden in wounds. They also provide accurate digital wound measurement for comprehensive wound management, supported by strong clinical evidence including over 100 peer-reviewed publications.

________________________________

1 Badrie S, Moore Z, Patton D, O'Connor T, Derwin R. The Clinical Utility of Autofluorescence Imaging for Bacterial Detection in Wounds: A Systematic Review. Int Wound J. 2025;22(6):e70678.

2 Le L, Baer M, Briggs P, Bullock N, et al. Diagnostic Accuracy of Point-of-Care Fluorescence Imaging for the Detection of Bacterial Burden in Wounds: Results from the 350-Patient Fluorescence Imaging Assessment and Guidance Trial. Adv Wound Care (New Rochelle). 2021;10(3):123-136. 

 

Photo - https://mma.prnewswire.com/media/2719217/MolecuLight_Landmark_Study_Affirms%C2%A0MolecuLight_s_Efficacy_in_Rea.jpg 
Photo - https://mma.prnewswire.com/media/2719216/MolecuLight_Landmark_Study_Affirms%C2%A0MolecuLight_s_Efficacy_in_Rea.jpg 

For sales, media or other inquiries or further information, please contact: MolecuLight Inc., Danielle Dunham, Director of Marketing and Product Management, T. +1.416.542.5524, [e-mail], www.moleculight.com

 

View original content:https://www.prnewswire.co.uk/news-releases/landmark-study-affirms-moleculights-efficacy-in-real-time-bacterial-detection-for-improved-wound-management-302491528.html